Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Prelude Therapeutics Inc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
7
12.1
Research and development
24.3
48.2
86.8
92.9
103
118
94.3
General and administrative
3.83
10.6
27
30.7
28.9
28.7
22.4
Operating expenses
28.1
58.8
114
124
132
147
117
Operating income
-28.1
-58.8
-114
-124
-132
-140
-105
Other non-operating income
0.54
1.83
2.04
8.1
10.4
12.5
5.07
Pre-tax income
-127
-99.5
Income tax
0
0
Net income
-27.6
-56.9
-112
-115
-122
-127
-99.5
EBITDA
-27.7
-58.2
-113
-122
-131
-138
-103
EPS, basic
-16.52
-4.56
-2.43
-2.44
-2.02
-1.68
-1.29
EPS, diluted
-16.52
-4.56
-2.43
-2.44
-2.02
-1.68
-1.29
Shares, basic (weighted)
1.67
12.5
46
47.4
60.4
75.8
77
Shares, diluted (weighted)
1.67
12.5
46
47.4
60.4
75.8
77
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
18.9
218
31.8
30.6
25.3
12.5
35.3
Short-term investments
259
171
208
121
68
Other current assets
1.35
2.5
3.88
2.65
2.65
2.28
2.48
Total current assets
20.2
221
295
204
236
136
106
Property, plant and equipment
1.65
2.48
3.93
4.91
7.33
6.77
5.11
Lease right-of-use assets
1.71
1.79
30.4
28.7
27.2
Total assets
21.9
224
305
221
278
176
141
Accounts payable
1.97
3.92
7.84
6.78
4.58
7.73
3.98
Accrued liabilities
2.6
7.46
9.62
13.1
15.8
15.2
12.5
Deferred revenue
0
33.7
Total current liabilities
4.84
11.4
19.2
21.7
21.8
25.6
53
Lease liabilities
15.4
15.3
15
Other non-current liabilities
0.01
0.03
0
3.36
3.34
3.09
2.84
Total liabilities
4.84
11.4
19.2
25.1
40.6
44.1
72.7
Paid-in capital
1.09
320
506
532
693
715
752
Retained earnings
-50.5
-107
-219
-335
-456
-584
-683
Other comprehensive income
-0.71
-1.69
0.22
0.04
0.01
Shareholders' equity
-49.4
212
286
195
237
131
68.6
Total equity
-49.4
212
286
195
237
131
68.6
Total liabilities and equity
21.9
224
305
221
278
176
141
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-27.6
-56.9
-112
-115
-122
-127
-99.5
Depreciation and amortization
0.38
0.54
0.92
1.32
1.17
1.77
1.71
Stock-based compensation
0.85
5.58
20.9
25.1
25.6
21.3
11.9
Change in payables
0.55
1.16
3.9
-0.35
-2.27
3.31
-3.92
Cash from operations
-25.7
-46.2
-83.5
-83.7
-107
-103
-56.3
Capital expenditures
-0.78
-0.62
-2.32
-3.02
-3.51
-0.76
-0.07
Purchases of investments
-261
-119
-222
-52.7
-101
Sales and maturities of investments
204
191
144
154
Cash from investing
-0.78
-0.62
-264
81.7
-34.6
90.2
53.5
Stock issued
0.01
0.1
161
0.39
0.05
0.06
0.02
Cash from financing
29.7
246
165
0.82
136
-0.12
24.8
Net change in cash
3.28
199
-182
-1.22
-5.31
-12.8
22
Free cash flow
-26.4
-46.8
-85.9
-86.7
-111
-104
-56.4
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.88 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-300.6%
Operating income / revenue.
EBITDA margin
-293.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-269.7%
Net income / revenue.
FCF margin
-148.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-148.3%
Cash from operations / revenue.
Return on equity (ROE)
-45.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-31.9%
Net income / average total assets.
Return on invested capital (ROIC)
-49.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
309.6%
Research and development expense / revenue.
Stock-based pay / revenue
37.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.0%
Capital expenditures / revenue.
D&A / revenue
7.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
73.4%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-47.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-29.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-20.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-19.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-13.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-8.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
17.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
43.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.07x
Current assets / current liabilities.
Quick ratio
3.99x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.99x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.23
Revenue / diluted weighted shares.
FCF per share
-$0.34
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.34
Cash from operations / diluted weighted shares.
Book value per share
$1.36
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
13.8x
Market cap / revenue.
P/B
2.31x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.31x
Market cap / tangible book value, when positive.
EV/Sales
7.02x
Enterprise value / revenue.
FCF yield
-10.8%
Free cash flow / market cap.
Earnings yield
-19.6%
Net income / market cap (the inverse of P/E).
What was Prelude Therapeutics Inc's revenue in fiscal 2025?
Prelude Therapeutics Inc reported revenue of $12.1M for fiscal 2025, 73.4% higher than the year before.
Was Prelude Therapeutics Inc profitable in fiscal 2025?
No. It reported a net loss of $99.5M.
How much free cash flow did Prelude Therapeutics Inc generate in fiscal 2025?
Cash from operations of $56.3M minus capital expenditures of $67.0K left free cash flow of -$56.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.